Allogene Therapeutics Inc (ALLO) — Financial Flexibility Index
Allogene Therapeutics Inc (ALLO) has a Financial Flexibility Index of -0.24x as of September 2025. Free cash flow of $-29.45 Million (operating CF $-29.69 Million minus capex $243.00K) represents 0% of total liabilities ($124.44 Million). Check Allogene Therapeutics Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Allogene Therapeutics Inc Financial Flexibility Index (2017–2024)
Historical Financial Flexibility Index trend for Allogene Therapeutics Inc across 8 annual periods. For the full cash flow conversion analysis, see ALLO operating cash flow.
Annual Financial Flexibility Index for Allogene Therapeutics Inc (2017–2024)
Year-by-year free cash flow to debt coverage for Allogene Therapeutics Inc. Explore ALLO cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.58x | $-199.61 Million | $-200.30 Million | $126.53 Million | ▲ +12.8% |
| 2023 | -1.81x | $-236.22 Million | $-237.73 Million | $130.60 Million | ▼ -29.9% |
| 2022 | -1.39x | $-215.33 Million | $-220.52 Million | $154.70 Million | ▼ -7.0% |
| 2021 | -1.30x | $-163.37 Million | $-184.81 Million | $125.63 Million | ▼ -292.3% |
| 2020 | -0.33x | $-49.13 Million | $-115.09 Million | $148.21 Million | ▲ +66.0% |
| 2019 | -0.97x | $-86.56 Million | $-137.35 Million | $88.78 Million | ▼ -66.4% |
| 2018 | -0.59x | $-41.42 Million | $-44.65 Million | $70.69 Million | ▲ +100.0% |
| 2017 | -19660.50x | $-39.32 Million | $-44.65 Million | $2.00K | — |